arrow_back Back to App

Animal Drug Fees Reauthorized: Faster Approvals and Stronger Fight Against Antibiotic Resistance.

This law reauthorizes the user fee programs for new and generic animal drugs until 2028, ensuring that pharmaceutical companies fund the FDA's review process to speed up drug approvals. This efficiency can lead to quicker access to necessary treatments for pets and livestock, and potentially lower costs for generic medications. Crucially, the act mandates enhanced reporting and activities focused on combating antimicrobial resistance in veterinary settings, which is vital for public health safety.
Key points
Extends industry funding for the FDA's animal drug review process through 2028, aiming for faster availability of new and generic animal medications.
Introduces new fees for companies seeking generic animal drug approval to streamline the regulatory workload.
Requires the FDA to report on and strengthen efforts to combat antimicrobial resistance in animals, protecting both animal and human health.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1418
Sponsor: Rep. Pence, Greg [R-IN-6]
Process start date: 2023-03-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Animal Drug and Animal Generic Drug User Fee Amendments of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1418.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-07.

What are the main provisions?

Key points include:

  • Extends industry funding for the FDA's animal drug review process through 2028, aiming for faster availability of new and generic animal medications.
  • Introduces new fees for companies seeking generic animal drug approval to streamline the regulatory workload.
  • Requires the FDA to report on and strengthen efforts to combat antimicrobial resistance in animals, protecting both animal and human health.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Pence, Greg [R-IN-6].

What is the latest detailed status?

The latest detailed status is: Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 210.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Agriculture